<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02171104</url>
  </required_header>
  <id_info>
    <org_study_id>2013LS104</org_study_id>
    <nct_id>NCT02171104</nct_id>
  </id_info>
  <brief_title>MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis</brief_title>
  <official_title>MT2013-31: Allogeneic Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Severe Osteopetrosis Following Conditioning With Busulfan (Therapeutic Drug Monitoring), Fludarabine +/- ATG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This single-institution, phase II study is designed to test the ability to achieve donor
      hematopoietic engraftment while maintaining low rates of transplant-related mortality (TRM)
      using busulfan- and fludarabine-based conditioning regimens with busulfan therapeutic drug
      monitoring (TDM) for patients with various inherited metabolic disorders (IMD) and severe
      osteopetrosis (OP).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 10, 2014</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of subjects who achieve high-level donor hematopoietic engraftment</measure>
    <time_frame>Day +42 post-transplant</time_frame>
    <description>Defined as neutrophil recovery by Day +42 post-transplant and ≥ 80% donor cells on the myeloid fraction of peripheral blood at Day +100 post-transplant</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of subjects who achieve high-level donor hematopoietic engraftment</measure>
    <time_frame>Day +100 post-transplant</time_frame>
    <description>Defined as ≥ 80% donor cells on the myeloid fraction of peripheral blood at Day +100 post-transplant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Graft-versus-host disease</measure>
    <time_frame>Day +100 post-transplant</time_frame>
    <description>Incidence and severity of GvHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant-related mortality</measure>
    <time_frame>Day +100 post-transplant</time_frame>
    <description>Incidence of TRM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Regimen-related toxicity</measure>
    <time_frame>Day +100 post-transplant</time_frame>
    <description>Defined as infection, acute renal failure, respiratory failure, cardiac failure, and veno-occlusive disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-HSCT changes in disease</measure>
    <time_frame>1 year</time_frame>
    <description>Incidence of radiographic, physiologic, neuro-psychologic, and/or biochemical aspects of the disease as assessed on a disease-specific basis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-HSCT changes in disease</measure>
    <time_frame>2 years</time_frame>
    <description>Incidence of radiographic, physiologic, neuro-psychologic, and/or biochemical aspects of the disease as assessed on a disease-specific basis</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Mucopolysaccharidosis Disorders</condition>
  <condition>Hurler Syndrome</condition>
  <condition>Hunter Syndrome</condition>
  <condition>Maroteaux Lamy Syndrome</condition>
  <condition>Sly Syndrome</condition>
  <condition>Alpha-Mannosidosis</condition>
  <condition>Fucosidosis</condition>
  <condition>Aspartylglucosaminuria</condition>
  <condition>Glycoprotein Metabolic Disorders</condition>
  <condition>Sphingolipidoses</condition>
  <condition>Recessive Leukodystrophies</condition>
  <condition>Globoid Cell Leukodystrophy</condition>
  <condition>Metachromatic Leukodystrophy</condition>
  <condition>Niemann-Pick B</condition>
  <condition>Niemann-Pick C Subtype 2</condition>
  <condition>Sphingomyelin Deficiency</condition>
  <condition>Peroxisomal Disorders</condition>
  <condition>Adrenoleukodystrophy With Cerebral Involvement</condition>
  <condition>Zellweger Syndrome</condition>
  <condition>Neonatal Adrenoleukodystrophy</condition>
  <condition>Infantile Refsum Disease</condition>
  <condition>Acyl-CoA Oxidase Deficiency</condition>
  <condition>D-Bifunctional Enzyme Deficiency</condition>
  <condition>Multifunctional Enzyme Deficiency</condition>
  <condition>Alpha-methylacyl-CoA Racmase Deficiency</condition>
  <condition>Mitochondrial Neurogastrointestingal Encephalopathy</condition>
  <condition>Severe Osteopetrosis</condition>
  <condition>Hereditary Leukoencephalopathy With Axonal Spheroids (HDLS; CSF1R Mutation)</condition>
  <condition>Inherited Metabolic Disorders</condition>
  <arm_group>
    <arm_group_label>IMD - Except Haplo-identical</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inherited Metabolic Disease (IMD) - Except Haplo-Identical
See intervention descriptions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OP - Except Haplo-Identical</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Severe Osteoperosis (OP) - Except Haplo-Identical
See intervention descriptions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OP and IMD -Haplo-Identical Only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Severe Osteopetrosis (OP) and Inhterited Metabolic Disorders (IMD)
-Haplo-Identical Only
See intervention descriptions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cALD SR-A (Standard-Risk, Regimen A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See intervention descriptions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cALD SR-B (Standard-Risk, Regimen B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See intervention descriptions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cALD HR-C (High-Risk, Regimen C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See intervention descriptions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>cALD HR-D (High-Risk, Regimen D)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See intervention descriptions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Stem Cell Transplantation</intervention_name>
    <description>Infusion given on Day 0</description>
    <arm_group_label>IMD - Except Haplo-identical</arm_group_label>
    <arm_group_label>OP - Except Haplo-Identical</arm_group_label>
    <arm_group_label>OP and IMD -Haplo-Identical Only</arm_group_label>
    <arm_group_label>cALD SR-A (Standard-Risk, Regimen A)</arm_group_label>
    <arm_group_label>cALD SR-B (Standard-Risk, Regimen B)</arm_group_label>
    <arm_group_label>cALD HR-C (High-Risk, Regimen C)</arm_group_label>
    <arm_group_label>cALD HR-D (High-Risk, Regimen D)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMD Preparative Regimen</intervention_name>
    <description>Anti-thymocyte Globulin (ATG)
Fludarabine
Busulfan</description>
    <arm_group_label>IMD - Except Haplo-identical</arm_group_label>
    <arm_group_label>cALD SR-A (Standard-Risk, Regimen A)</arm_group_label>
    <arm_group_label>cALD SR-B (Standard-Risk, Regimen B)</arm_group_label>
    <arm_group_label>cALD HR-C (High-Risk, Regimen C)</arm_group_label>
    <arm_group_label>cALD HR-D (High-Risk, Regimen D)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osteopetrosis Only Preparative Regimen</intervention_name>
    <description>Anti-thymocyte Globulin (ATG)
Fludarabine
Busulfan
Thiotepa</description>
    <arm_group_label>OP - Except Haplo-Identical</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osteopetrosis Haploidentical Only Preparative Regimen</intervention_name>
    <description>Rituximab
Alemtuzumab
Busulfan
Fludarabine</description>
    <arm_group_label>OP and IMD -Haplo-Identical Only</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cALD SR-A (Standard-Risk, Regimen A)</intervention_name>
    <description>N-acetylcysteine start day +1 through day +28</description>
    <arm_group_label>cALD SR-A (Standard-Risk, Regimen A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cALD SR-B (Standard-Risk, Regimen B)</intervention_name>
    <description>N-acetylcysteine start day +1through day +56</description>
    <arm_group_label>cALD SR-B (Standard-Risk, Regimen B)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cALD HR-D (High-Risk, Regimen C)</intervention_name>
    <description>N-acetylcysteine and celecoxib start day of admission (prior to conditioning regimen) and continue through day +100</description>
    <arm_group_label>cALD HR-C (High-Risk, Regimen C)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cALD HR-D (High-Risk, Regimen D)</intervention_name>
    <description>N-acetylcysteine, celecoxib, vitamin E and alpha lipoic acid start day of admission (prior to conditioning regimen) and continue through day +100</description>
    <arm_group_label>cALD HR-D (High-Risk, Regimen D)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  0 through 55 years of age

          -  Adequate graft available

          -  Adequate organ function

          -  Eligible Diseases:

               -  Mucopolysaccharidosis Disorders:

                    -  MPS IH (Hurler syndrome)

                    -  MPS II (Hunter syndrome) if the patient has no or minimal evidence of
                       symptomatic neurologic disease but is expected to have a neurologic
                       phenotype

                    -  MPS VI (Maroteaux-Lamy syndrome)

                    -  MPS VII (Sly syndrome)

               -  Glycoprotein Metabolic Disorders:

                    -  Alpha mannosidosis

                    -  Fucosidosis

                    -  Aspartylglucosaminuria

               -  Sphingolipidoses and Recessive Leukodystrophies:

                    -  Globoid cell leukodystrophy

                    -  Metachromatic leukodystrophy

                    -  Niemann-Pick B patients (sphingomyelin deficiency)

                    -  Niemann-Pick C subtype 2

               -  Peroxisomal Disorders:

                    -  Adrenoleukodystrophy with cerebral involvement

                    -  Zellweger syndrome

                    -  Neonatal Adrenoleukodystrophy

                    -  Infantile Refsum disease

                    -  Acyl-CoA-Oxidase Deficiency

                    -  D-Bifunctional enzyme deficiency

                    -  Multifunctional enzyme deficiency

                    -  Alpha-methylacyl-CoA Racmase Deficiency (AMACRD)

                    -  Mitochondrial Neurogastrointestingal Encephalopathy (MNGIE)

               -  Severe Osteopetrosis (OP)

               -  Hereditary Leukoencephalopathy with axonal spheroids (HDLS; CSF1R mutation)

               -  Other Inherited Metabolic Disorders (IMD): Patients will also be considered who
                  have other life-threatening, rare lysosomal, peroxisomal or other similar
                  inherited disorders characterized by white matter disease or other neurologic
                  manifestations for which there is rationale that transplantation would be of
                  benefit, such as certain patients with Wolman's disease, GM1 gangliosidosis,
                  I-cell disease, Tay-Sachs disease, Sandhoff disease or others.

               -  Voluntary written consent

        Exclusion Criteria:

          -  Pregnancy - menstruating females must have a negative serum or urine pregnancy test
             within 14 days of study treatment start

          -  Prior myeloablative chemotherapy exposure within 4 months of the start of conditioning
             on this protocol (patients excluded for this reason may be eligible for other
             institutional protocols)

          -  Uncontrolled bacterial, fungal or viral infections including HIV (including active
             infection with Aspergillus or other mold within 30 days)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Orchard, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kim Nelson</last_name>
    <phone>612-273-2925</phone>
    <email>knelso62@fairview.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Troy Lund, M.D.Ph.D.</last_name>
    <phone>612-625-4185</phone>
    <email>lundx072@umn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Nelson</last_name>
      <phone>612-273-2925</phone>
      <email>knelso62@fairview.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 20, 2014</study_first_submitted>
  <study_first_submitted_qc>June 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2014</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>allogeneic hematopoietic cell transplantation</keyword>
  <keyword>bone marrow transplantation</keyword>
  <keyword>IMD</keyword>
  <keyword>AMACRD</keyword>
  <keyword>MNGIE</keyword>
  <keyword>HDLS</keyword>
  <keyword>OP</keyword>
  <keyword>ALD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Mucopolysaccharidoses</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
    <mesh_term>Adrenoleukodystrophy</mesh_term>
    <mesh_term>Leukodystrophy, Metachromatic</mesh_term>
    <mesh_term>Leukoencephalopathies</mesh_term>
    <mesh_term>Mannosidase Deficiency Diseases</mesh_term>
    <mesh_term>alpha-Mannosidosis</mesh_term>
    <mesh_term>Mucopolysaccharidosis I</mesh_term>
    <mesh_term>Osteopetrosis</mesh_term>
    <mesh_term>Leukodystrophy, Globoid Cell</mesh_term>
    <mesh_term>Sphingolipidoses</mesh_term>
    <mesh_term>Mucopolysaccharidosis VI</mesh_term>
    <mesh_term>Peroxisomal Disorders</mesh_term>
    <mesh_term>Mucopolysaccharidosis VII</mesh_term>
    <mesh_term>Fucosidosis</mesh_term>
    <mesh_term>Aspartylglucosaminuria</mesh_term>
    <mesh_term>Zellweger Syndrome</mesh_term>
    <mesh_term>Refsum Disease, Infantile</mesh_term>
    <mesh_term>Refsum Disease</mesh_term>
    <mesh_term>Intestinal Pseudo-Obstruction</mesh_term>
    <mesh_term>Mitochondrial Encephalomyopathies</mesh_term>
    <mesh_term>Hearing Loss, Sensorineural</mesh_term>
    <mesh_term>Gonadal Dysgenesis, 46,XX</mesh_term>
    <mesh_term>Lipid Metabolism, Inborn Errors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

